Navigation Links
Sangamo BioSciences Announces Fourth Quarter And Full Year 2012 Conference Call And Webcast
Date:1/30/2013

RICHMOND, Calif., Jan. 30, 2013 /PRNewswire/ -- Sangamo BioSciences, Inc. (Nasdaq: SGMO) today announced that the company will release its fourth quarter and full year 2012 financial results on Wednesday, February 6, 2013, after the market closes. The press release will be followed by a conference call at 5:00 p.m. ET, which will be open to the public via telephone and webcast. During the conference call, the company will review the financial results and discuss other business matters.

(Logo: http://photos.prnewswire.com/prnh/20130102/SF35903LOGO)

The conference call dial-in numbers are 877-377-7553 for domestic callers and 678-894-3968 for international callers. The passcode for the call is 92659211.  Participants may access the live webcast via a link on the Sangamo BioSciences website in the Investors section under Events and Presentations. For those unable to listen in at the designated time, a conference call replay will be available for one week following the conference call, from approximately 8:00 p.m. ET on February 6, 2013 to 11:59 p.m. ET on February 13, 2013. The conference call replay numbers for domestic and international callers are 855-859-2056 and 404-537-3406, respectively. The conference ID number for the replay is 92659211.

About Sangamo
Sangamo BioSciences, Inc. is focused on research and development of novel DNA-binding proteins for therapeutic gene regulation and genome editing. The Company has ongoing Phase 2 clinical trials to evaluate the safety and efficacy of a novel ZFP Therapeutic® for the treatment of HIV/AIDS. Sangamo's other therapeutic programs are focused on monogenic diseases, including hemophilia, Huntington's disease and  hemoglobinopathies such as sickle cell anemia and beta-thalassemia. Sangamo's core competencies enable the engineering of a class of DNA-binding proteins known as zinc finger DNA-binding proteins (ZFPs).  Engineering of ZFPs that recognize a specific DNA sequence enables the creation of sequence-specific ZFP Nucleases (ZFNs) for gene modification and ZFP transcription factors (ZFP TFs) that can control gene expression and, consequently, cell function. Sangamo has entered into a strategic collaboration with Shire AG to develop therapeutics for hemophilia, Huntington's disease and other monogenic diseases, and it has also established strategic partnerships with companies in non-therapeutic applications of its technology including Dow AgroSciences and Sigma-Aldrich Corporation. For more information about Sangamo, visit the company's website at www.sangamo.com
ZFP Therapeutic® is a registered trademark of Sangamo BioSciences, Inc.


'/>"/>
SOURCE Sangamo BioSciences, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related biology technology :

1. Sangamo BioSciences Announces Presentation At The Lazard Capital Markets Healthcare Conference
2. Sangamo BioSciences Announces Presentation At The Stifel Nicolaus 2012 Healthcare Conference
3. Sangamo BioSciences Announces Second Quarter 2012 Conference Call and Webcast
4. Sangamo BioSciences Announces Presentation at Seventh Annual JMP Securities Healthcare Conference
5. Sangamo BioSciences Announces Presentations At Upcoming Investor Conferences
6. Sangamo BioSciences Reports First Quarter 2012 Financial Results
7. Sangamo BioSciences Announces First Quarter 2012 Conference Call and Webcast
8. Sangamo BioSciences Announces Fourth Quarter and Full Year 2011 Conference Call and Webcast
9. Sangamo BioSciences Announces Presentation at J.P. Morgan Healthcare Conference
10. Sangamo BioSciences Announces Presentation of New Data from ZFP Therapeutic® Program in Hemophilia B at American Society for Hematology Meeting
11. IntelliCell BioSciences Announces the Addition of Harry Fisch, MD as Director of Urology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/21/2017)... 2017 Aratana Therapeutics, Inc. (NASDAQ: ... licensing, development and commercialization of innovative biopharmaceutical products for ... in North America 2016. ... based on the FDA approval of three innovative therapeutics ... (capromorelin oral solution) and NOCITA ® (bupivacaine ...
(Date:1/20/2017)... -- Ginkgo Bioworks, the organism company, announced today ... synthesis and assembly of DNA. The acquisition will ... DNA into Ginkgo,s automated organism engineering foundries, enabling ... new organism designs for application across a wide ... to significantly increase the world,s capacity to cost-effectively ...
(Date:1/19/2017)...  Market Research Future has a half cooked research report on ... growing rapidly and expected to reach USD 450 Million by the ... ... has been assessed as a swiftly growing market and expected that ... coming future. There has been a tremendous growth in the prevalence ...
(Date:1/19/2017)... ... January 19, 2017 , ... ... solutions for pharmaceutical research and development (R&D), today announced the launch of ... analysis and interpretation for the rapidly evolving field of precision medicine. ...
Breaking Biology Technology:
(Date:1/6/2017)... 2017  Privately-held CalciMedica, Inc., announced that it ... of a novel calcium release-activated calcium (CRAC) channel ... Acute pancreatitis, sudden painful inflammation of ... can be very serious.  In severe cases it can ... hospital stays, time in the ICU and substantial ...
(Date:1/4/2017)... 2017  CES 2017 – Valencell , the ... announced the launch of two new versions of ... biometric sensor modules that incorporate the best of ... expertise. The two new designs include Benchmark BE2.0, ... and Benchmark BW2.0, a 2-LED version of its ...
(Date:12/20/2016)... , Dec. 20, 2016 The ... sharing, rental and leasing is stoking significant interest ... radio frequency technology, Bluetooth low energy (BLE), biometrics ... as the next wave of wireless technologies in ... access system to advanced access systems opens the ...
Breaking Biology News(10 mins):